COSEHC’s 9th National Scientific Sessions
October 17 – 19, 2002
The Westin Savannah Harbor Resort
Savannah, Georgia

Protecting and Treating The Cardiovascular Target Organs in the Context of the Whole Patient: A Parting of the Ways?

Jointly sponsored by

www.cosehc.org

Photo From The Savannah Morning News
Dear COSEHC Members and Meeting Participants:

The 9th National Scientific Sessions of COSEHC promise to be the best ever. Our theme this year is “Protecting and Treating the Cardiovascular Target Organs (Brain, Heart and Kidney) in the Context of the Whole Patient: A Parting of the Ways”.

Some of the most dynamic experts in their respective fields will discuss and debate important clinical issues to prevent and treat target organ damage. Does the means justify the end? Are there differences in target organ response to varied classes of antihypertensive agents? How should we select our drug armamentarium in the content of the whole patient as opposed to a specific target organ? Are the non-hypertensive effects of antihypertensive drugs and the non-lipid effects of the anti-lipid drugs important clinically?

These and other important topics will be discussed and debated. Additional time for panel and audience discussion has been added to the program. All participants will receive a detailed syllabus of the speakers lecture slides and notes. A defined time to visit the posters and abstracts will be available along with an Awards Banquet.

This is an education experience of a lifetime. You will not want to miss it. Basic science will be transported to the bedside for immediate clinical application and treatment of patients.

We hope to see you in Savannah, Georgia on October 17-19, 2002.

Mark Houston, M.D., FACP, FAHA
COSEHC 2002 Co-Chair

Leopoldo Raij, M.D.
COSEHC 2002 Co-Chair

Rafael Sequeira, M.D.
COSEHC 2002 Co-Chair
Need

47 Million Americans are hypertensive, with greater than one-third of those residing in the Southeast. Basic science research is ongoing in both academic and clinical settings, with significant data being captured and analyzed regarding the factors and mechanisms underlying the high incidence of cardiovascular disease in the Southeast. There are existing and emerging resources available to support the detection, treatment and prevention of cardiovascular disease, providing healthcare professionals are well-informed and able to properly apply these resources within their practice settings.

Purpose

The 2002 COSEHC conference will bring together healthcare professionals throughout the region to focus on issues and new guidelines for managing the global risk of cardiovascular disease in the Southeast. Through intensive lectures, discussions, concurrent sessions and collegial interaction, participants should gain a better understanding of cardiovascular disease in the Southeast and be better prepared to improve disease management and patient outcomes.

Educational Method

Intensive lecture format.

Objectives

At the conclusion of this program, participants should be able to:

- Apply the principles of treatment of hypertension as set forth in JNC-VI standards;
- Discuss the epidemiology and risk factors contributing to cardiovascular disease;
- Recognize and apply newer approaches to antihypertensive therapy;
- Assess and treat hypertensive patients from special populations;
- Optimize patient management strategies in end-stage renal disease and cardiorenal failure;
- Implement positive health behaviors in hypertensive patients; and
- Provide primary care in the treatment of the hypertensive patient.

Target Audience

Private practice and academic physicians, nurses, health care providers, managed care providers, research scientists, and public health service personnel.

Information presented may be of interest and benefit to related healthcare professionals who manage patients with hypertension, dyslipidemia and diabetes.

CME Designation

The Medical University of South Carolina designates this educational activity for a maximum of 22.5 hours in Category 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical University of South Carolina and COSEHC. The Medical University of South Carolina is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure

The Medical University of South Carolina adheres to ACCME Standards regarding industry support of continuing medical education, and disclosure of faculty and commercial support relationships, if any, will be made known at the conference.

Americans with Disabilities Act

It is the policy of the Medical University of South Carolina not to discriminate against any person on the basis of disabilities. If you feel you need services or the auxiliary aids mentioned in this act in order to fully participate in this continuing medical education activity, please call the Office of CME at (843) 876-1925 or attach a note to your registration.

Speaker Disclosure

The Medical University of South Carolina endorses the Standards of the Accreditation Council for Continuing Medical Education and Guidelines of the Association of American Medical Colleges that sponsors continuing medical education activities. The presenters at these activities should disclose significant relationships with commercial companies whose products or services are discussed in educational presentations.
**Conference Details**

**Supporters**

_COSEHC gratefully acknowledges the following companies for their unrestricted educational grants._

- Bristol Myers Squibb
- Sankyo
- Merck & Co., Inc.
- Solvay
- Novartis
- Takeda
- Pfizer

**Exhibit Hours**

- Wednesday, 5:00 pm-9:00 pm ........................................................................... Exhibit Set-Up
- Thursday, 3:00 pm-7:00 pm
- Friday, 8:00 am-5:00 pm
- Saturday, 8:00 am-5:00 pm
- Saturday, 8:00 am-3:00 pm ........................................................................... Exhibit Tear Down

**Registration Hours**

- Wednesday, 5:00 pm-8:00 pm
- Thursday, 8:00 am-8:00 pm
- Friday, 7:00 am-7:00 pm
- Saturday, 7:00 am-2:00 pm

**Hotel Information**

_Savannah Westin Harbor Resort_
_One Resort Drive, Savannah, Georgia 31402_

_Call Hotel directly and ask for COSEHC Room Block: 912-201-2000._

_Guest Fax 912-201-2001_

_Room Rates: Week day rates $189.00 plus a service fee of $12.00 to cover health club access, in-room coffee, local telephone calls, self-parking, daily newspapers, and water taxi._
New Investigator Candidates

We are calling for applications for candidates for the 2002 COSEHC New Investigator Award. The intent of the award is to recognize promising new investigators in the field of cardiovascular research. Candidates should provide a curriculum vitae, statement of career interests along with one letter of recommendation and submit an abstract.

The deadline for receipt of applications is September 1, 2002 for the 2002 COSEHC meeting. Please phone (336-716-2150); Fax (336-716-2456) or e-mail (ddiz@wfubmc.edu) for further information. Application material should be sent to Debra I. Diz., Ph.D., Professor, COSEHC Awards Committee Chair, Hypertension and Vascular Disease Center, WFU Baptist Medical Center, Winston-Salem, NC 27157-1032.

Guidelines for COSEHC New Investigator Awards:

Purpose of the award: To recognize a promising newly independent investigator, working in the field of hypertension or cardiovascular research.

Qualifications: Candidates should not be more than 10 years from the date of receiving the Ph.D. or more than 10 years post-fellowship for those having an M.D. or D.O.

How decisions will be made: The candidates should submit a curriculum vitae along with a statement of their research/career and two letters of recommendation. The basis for the award will include publications (number, quality and clear evidence of interest in the area of hypertension) and commitment of the individual to develop an independent laboratory.

Awards Committee members will rank the candidates on the basis of the biographic information and knowledge of the candidate from meetings and presentation.

Awards will be voted upon by the members of the awards Committee. The presentation of the award will be made at the awards banquet at the annual meeting.

Award: At the annual meeting the awardee will be presented with a check for $1000 and COSEHC will reimburse meeting travel expenses.

Past Awardees:
1995 Dr. Kathryn Sandberg 1998 Dr. Carla Yunis 2000 Dr. Craig Gelband
1996 Dr. Daniel Jones 1999 Dr. George Mensah 2001 Dr. Jiang He
1997 Dr. David Calhoun
**Thursday, October 17, 2002**

**1:00 pm – 5:00 pm**

**Board of Director's Meeting**

*Meeting Officially Begins*

**6:30 pm – 9:30 pm**

**DINNER SYMPOSIUM**

*Arrive by 6:15 pm to be seated*

*Protecting the Vascular System: The Role of Vascular Biology, Surrogate Markers and Clinical Outcomes in the Selection of Antihypertensive and Anti-Lipid Therapy*

*Chairs: Carlos Ferrario, M.D. and Michael Moore, M.D.*

**6:30 pm – 7:00 pm**

*Vascular Biology: Clinical Application and Overview*

Gary Gibbons, M.D.

**7:00 pm – 8:00 pm**

*Pleiotrophic Vascular Effects of Statins: Vascular Biology Effects, Anti-Hypertensive, Anti-Diabetic, Cardioprotective, Cerebroprotective, Renoprotective and Anti-Thrombotic Effects*

Carlos Ferrario, M.D. and Eric Dyess, M.D.

**8:00 pm – 9:00 pm**

*Vascular Effects of Antihypertensive Drugs*

Brent Egan, M.D. and Michael Moore, M.D.

**9:00 pm – 9:30 pm**

*Panel Discussion/Questions & Answers/Debate*

---

*We gratefully acknowledge an unrestricted educational grant from Sankyo*
### Debate on Hypertension

**Beta Blockers or Beta Baggage in the Primary Treatment of Hypertension**

Chair: Michael Moore, M.D.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 7:25 am</td>
<td>Pro: Thomas Giles, M.D.</td>
</tr>
<tr>
<td>7:25 am – 7:50 am</td>
<td>Con: Franz Messerli, M.D.</td>
</tr>
<tr>
<td>7:50 am – 7:55 am</td>
<td>Rebuttal: Thomas Giles, M.D.</td>
</tr>
<tr>
<td>7:55 am – 8:00 am</td>
<td>Rebuttal: Franz Messerli, M.D.</td>
</tr>
<tr>
<td>8:00 am – 8:25 am</td>
<td>Q&amp;A: Audience and Panel</td>
</tr>
<tr>
<td>8:25 am – 8:30 am</td>
<td>Summary Remarks: William Cushman, M.D. and Michael Moore, M.D.</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Adjourn</td>
</tr>
<tr>
<td>8:30 am – 8:40 am</td>
<td>BREAK</td>
</tr>
</tbody>
</table>

### SESSION I

**The Heart**

**Blocking the Blockage & Priming the Pump**

Chairs: Rafael Sequeira, M.D. and Michael Prisant, M.D.

**PART I**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:40 am – 8:45 am</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td>Mark Houston, M.D.</td>
</tr>
<tr>
<td>8:45 am – 9:15 am</td>
<td>Pathophysiology of Atherosclerosis, Thrombosis and Coronary Heart Disease</td>
</tr>
<tr>
<td></td>
<td>Doug Vaughan, M.D.</td>
</tr>
<tr>
<td>9:15 am – 9:45 am</td>
<td>Coronary Artery Morbidity &amp; Mortality: The EUROPA Trial</td>
</tr>
<tr>
<td></td>
<td>Carlos Ferrario, M.D.</td>
</tr>
<tr>
<td>9:45 am – 10:00 am</td>
<td>Panel Discussion/Questions &amp; Answers</td>
</tr>
</tbody>
</table>

**PART II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am –10:30 am</td>
<td>Pathophysiology of Systolic &amp; Diastolic Congestive Heart Failure</td>
</tr>
<tr>
<td></td>
<td>Rafael Sequeira, M.D.</td>
</tr>
<tr>
<td>10:30 am–11:00 am</td>
<td>Clinical Trials in CHF</td>
</tr>
<tr>
<td></td>
<td>Jay Cohn, M.D.</td>
</tr>
<tr>
<td>11:00 am–11:30 am</td>
<td>Practical Clinical Management of CHF</td>
</tr>
<tr>
<td></td>
<td>Thomas Giles, M.D.</td>
</tr>
<tr>
<td>11:30 – 12:00 noon</td>
<td>Panel Discussion/Questions &amp; Answers</td>
</tr>
<tr>
<td></td>
<td>Adjourn</td>
</tr>
<tr>
<td></td>
<td>BREAK</td>
</tr>
</tbody>
</table>

---

*We gratefully acknowledge an unrestricted educational grant from Novartis*
### Friday, October 18, 2002

#### 12:00 noon – 2:00 pm

**LUNCH SYMPOSIUM**  
*Nonpharmacologic Treatment and Lifestyle Modification in the Prevention and Treatment of HBP*  
Chair: Brent Egan, M.D.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 noon – 12:30 pm</td>
<td>Nutrition</td>
<td>Lawrence Appel, M.D.</td>
</tr>
<tr>
<td>12:30 pm – 1:00 pm</td>
<td><em>Nutraceuticals, Vitamins, Antioxidants</em></td>
<td>Mark Houston, M.D.</td>
</tr>
<tr>
<td>1:00 pm – 1:30 pm</td>
<td>Exercise</td>
<td>Ileana Pina, M.D.</td>
</tr>
<tr>
<td>1:30 pm – 2:00 pm</td>
<td><em>Panel Discussion/Questions &amp; Answers</em></td>
<td></td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
<tr>
<td>2:00 pm – 2:15 pm</td>
<td>BREAK</td>
<td></td>
</tr>
</tbody>
</table>

#### 2:15 pm – 5:00 pm

**SESSION II**  
*The Brain*  
*Saving and Renewing Neurons for a Masterful Mind*  
Chair: Philip Gorelick, M.D. and Daniel T. Lackland, DrPH

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 pm – 2:45 pm</td>
<td><em>Primary Prevention of Ischemic Stroke and Intracranial Hemorrhage</em></td>
<td>Timothy Carter, M.D.</td>
</tr>
<tr>
<td>2:45 pm – 3:15 pm</td>
<td><em>Secondary Prevention of CVA: Ischemic CVA and ICH PROGRESS Study</em></td>
<td>Philip Gorelick, M.D.</td>
</tr>
</tbody>
</table>

*We gratefully acknowledge an unrestricted educational grant from Solvay*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 pm – 3:45 pm</td>
<td><em>Management of Hypertension in the Setting of An Acute CVA</em></td>
<td>Michael Kaminski, M.D.</td>
</tr>
<tr>
<td>3:45 pm – 4:15 pm</td>
<td><em>Cerebrovascular and Multi-Infarct Dementia</em></td>
<td>Charles Tegeler, M.D.</td>
</tr>
<tr>
<td>4:15 pm – 5:00 pm</td>
<td><em>Panel Discussion/Questions &amp; Answers</em></td>
<td></td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

#### 5:00 pm – 7:00 pm

**Poster Session Symposium**  
Chair: William Strawn, DVM, PhD

#### 7:00 pm – 9:00 pm

**AWARDS DINNER**

---

www.cosehc.org
### Saturday, October 19, 2002

#### 7:00 am – 8:30 am
**BREAKFAST SYMPOSIUM**

**Debate on Dyslipidemia**
- Are Statins Enough?
- Is a Lower LDL Better?
- Does Particle Size Matter?
- Good or Bad Membranes & Blood Vessels?

Chairs: Carlos Ferrario, M.D. and Jan Basile, M.D.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 7:25 am</td>
<td>Pro: TBA</td>
</tr>
<tr>
<td>7:25 am – 7:50 am</td>
<td>Con: Sergio Fazio, M.D.</td>
</tr>
<tr>
<td>7:50 am – 7:55 am</td>
<td>Rebuttal: TBA</td>
</tr>
<tr>
<td>7:55 am – 8:00 am</td>
<td>Rebuttal: Sergio Fazio, M.D.</td>
</tr>
<tr>
<td>8:00 am – 8:25 am</td>
<td>Q&amp;A: Audience and Panel</td>
</tr>
<tr>
<td>8:25 am – 8:30 am</td>
<td>Summary Remarks: Carlos Ferrario, M.D. and Jan Basile, M.D.</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Adjourn</td>
</tr>
<tr>
<td>8:30 am – 8:45 am</td>
<td>BREAK</td>
</tr>
</tbody>
</table>

#### 8:45 am – 12:00 noon
**SESSION III**

**The Kidney: Fine Tuning the Filter & the Flow**
Chair: Leopoldo Raij, M.D.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 am – 9:15 am</td>
<td><em>Pathophysiology of Microalbuminuria, Proteinuria and Nephron Loss</em> Tony Guasch, M.D.</td>
</tr>
<tr>
<td>9:15 am – 9:45 am</td>
<td><em>The Role of Diuretics in Renal Disease: Nephrotoxic or Renoprotective</em> Domenic Sica, M.D.</td>
</tr>
<tr>
<td>9:45 am – 10:15 am</td>
<td><em>Interrupting the Renin-Angiotensin-Aldosterone System (RAAS) in the Prevention &amp; Treatment of Renal Disease and Proteinuric States</em> Michael Moore, M.D.</td>
</tr>
<tr>
<td>10:15 am – 10:45 am</td>
<td><em>Recent Trials in Diabetic Renal Disease</em> Robert Toto, M.D.</td>
</tr>
<tr>
<td>10:45 am – 11:45 am</td>
<td><em>Multiple Drug Therapies as a Requisite for Achieving Blood Pressure Control in the Renal Patient</em> Murray Epstein and Leopoldo Raij, M.D.</td>
</tr>
<tr>
<td>11:45 am – 12:00 noon</td>
<td><em>Angiotensin II Blockade &amp; Cardiovascular Mortality</em> Carlos M. Ferrario, M.D.</td>
</tr>
</tbody>
</table>

---

*We gratefully acknowledge an unrestricted educational grant from Merck*
### Saturday, October 19, 2002

#### 12:00 noon – 1:30 pm

**LUNCH SYMPOSIUM**

**Vasopeptidase Inhibition: A New Frontier**  
Chair: Carlos Ferrario, M.D.

12:00 pm – 12:20 pm  
**Vasoactive Mechanism & Blood Pressure Regulation in Salt-Sensitive Hypertension**  
Carlos M. Ferrario, M.D.

12:20 pm – 12:40 pm  
**Octave Trial**  
John Kostis, M.D.

12:40 pm – 1:00 pm  
**Special Populations**  
Luther Clark, M.D.

1:00 pm – 1:30 pm  
**Panel Discussion/Questions & Answers**

1:30 pm

**We gratefully acknowledge an unrestricted educational grant from Bristol Myers Squibb**

#### 2:15 pm – 5:15 pm

**SESSION IV**

**The Whole Patient: Putting It All Together**  
*Diagnosis, Prevention and Treatment of Vascular Disease and the Dysmetabolic Syndrome*  
Chair: Mark Houston, M.D. and Ralph Hawkins, M.D.

2:15 pm – 2:45 pm  
**Oxidative Stress, Antioxidants, Endothelial Dysfunction (ED), Vascular Disease and Atherosclerosis**  
Emile Mohler, M.D.

2:45 pm – 3:15 pm  
**Early Non-Invasive Detection of ED, Vascular Disease and Atherosclerosis: The Dysmetabolic Syndrome**  
Robert A. Vogel, M.D.

3:15 pm – 3:45 pm  
**Early and Aggressive Treatment of ED, Vascular Disease and Atherosclerosis**  
Carlos Ferrario, M.D.

3:45 pm – 4:15 pm  
**Does Vascular Biology Play a Role in the Selection of Antihypertensive Drugs and Subsequent Clinical Outcomes?**  
Mark Houston, M.D.

4:15 pm – 4:45 pm  
**Specific Goals and Recommendations for the Management of Hypertension, Hyperlipidemia and Diabetes Mellitus to Reduce CHD, CHF, CVA, CRI, Carotid and PAD: A Clinician’s Point of View**  
Jan Basile, M.D.

4:45 pm – 5:15 pm  
**Panel Discussion/Questions & Answers**

5:15 pm  
Adjourn
Saturday, October 19, 2002

6:30 pm – 9:00 pm

The Master's Debate:
Bridging Research and Clinical Treatment with
Clinical Outcomes to Reduce Target Organ Damage in Hypertension
Chair: Paul Whelton, M.D.

6:30 pm – 6:40 pm
Diuretics
Marco Pahor, M.D.

6:40 pm – 6:50 pm
Beta Blockers
TBA

6:50 pm – 7:00 pm
Calcium Blockers
Murray Epstein, M.D.

7:00 pm – 7:10 pm
ACEI's
Ronald Smith, M.D.

7:10 pm – 7:20 pm
ARB's
Michael Moore, M.D.

7:20 pm – 7:30 pm
Alpha Blockers
Michael Prisant, M.D.

7:30 pm – 7:40 pm
Central Alpha Agonists
Elijah Saunders, M.D.

7:40 pm – 7:50 pm
Vasopeptidase Inhibitors (VPI's)
Jan Basile, M.D.

7:50 pm – 8:00 pm
Summary
ALLHAT Perspective
Paul Whelton, M.D.

8:00 pm – 9:00 pm
Questions & Answers/Debate/Discussion

We gratefully acknowledge an unrestricted educational grant from Pfizer
Lawrence Appel, MD, MPH
Associate Professor, John Hopkins Medical Institutions, Baltimore, MD

Jan Basile, MD
Associate Professor of Medicine, Director Hypertension Section, VA Hospital/Medical University of South Carolina, Charleston, SC

Timothy Carter, MD
Vice Chair for Clinical Affairs, Medical University of South Carolina, Charleston, SC

Luther Clark, MD
Professor, State University of New York, Brooklyn, NY

Jay Cohn, MD
Professor of Medicine, Minneapolis, MN

Debra I. Diz, PhD
Professor, Hypertension & Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC

Eric Dyess, MD
Private Practice, Ridgeland, MS

Brent M. Egan, MD
Professor of Medicine & Pharmacology, Medical University of South Carolina, Charleston, SC

Murray Epstein, MD
Professor of Medicine, University of Miami School of Medicine, Miami, FL

Sergio Fazio, MD, PhD
Associate Professor of Cardiology, Vanderbilt University School of Medicine, Nashville, TN

Carlos Ferrario, MD
Professor & Director, Hypertension & Vascular Disease Center, Wake Forest University School of Medicine, President, COSEHC, Winston-Salem, NC

Gary H. Gibbons, MD
Associate Professor of Medicine, Director of Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, GA

Thomas D Giles, MD
Professor, LSU School of Medicine, New Orleans, LA

Philip B. Gorelick, MD
Professor & Director, Section of Cerebrovascular Disease, Rush Presbyterian St. Luke's Medical Center, Chicago, IL

Tony Gausch, MD
Nephrology, Emory University School of Medicine, Atlanta, GA

Ralph Hawkins, MD
Private Practice, Memphis, TN

Mark Houston, MD
Clinical Professor of Medicine, Vanderbilt University School of Medicine, Nashville, TN

Michael Kaminski, MD
St. Thomas Hypertension Institute, Nashville, TN

John Kostis, MD
Professor & Chair, Internal Medicine, Robert Wood Johnson University Hospital, New Brunswick, NJ

University Hospital, New Brunswick, NJ

Daniel T. Lackland, DrPH
Professor, Dept. of Biometry & Epidemiology, Charleston, SC

Franz H. Messerli, MD
Ochsner Clinic, New Orleans, LA

Emile R. Mohler III, MD
Assistant Professor of Medicine, University of Pennsylvania Health System, Philadelphia, PA

Michael Moore, MD
Professor, Wake Forest University School of Medicine, Secretary/Treasurer, COSEHC, Winston-Salem, NC

Marco Pahor, MD
Professor, Director of J. Paul Sticht Center on Aging, Wake Forest University School of Medicine, Winston-Salem, NC

Ileana L. Pina, MD
Professor, Case Western University Reserve, Cleveland, OH

Michael Prisant, MD
Internal Medicine and Associate Chairman, Medical College of Georgia, Martinez, GA

Leopoldo Raij, MD
Professor of Medicine, Director of Hypertension; Nephrology & Hypertension Division, Vice Chair, Vascular Biology Institute, University of Miami School of Medicine, Miami, FL

Elijah Saunders, MD
Professor of Medicine, University of Maryland, Baltimore, MD

Rafael F. Sequeira, MD
Professor of Medicine, Director, Coronary Care Unit, University of Miami School of Medicine, Miami, FL

Domenic Sica, MD
Professor & Division Head, Medical College of Virginia, Richmond, VA

Ronald A. Smith, MD
Professor, Wake Forest University School of Medicine, Winston-Salem, NC

William Straw, PhD, DVM
Assistant Professor, Wake Forest University School of Medicine

Charles Tegeler, MD
Professor, Neurology, Wake Forest University School of Medicine, Winston-Salem, NC

Robert Toto, MD
Professor of Medicine, Dallas Nephrology Associates, Dallas, TX

Doug Vaughan, MD
Chief, Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, TN

Robert A. Vogel, MD
Director, Clinical Vascular Biology, University of Maryland School of Medicine, Baltimore, MD

Paul Whelton, MD, MSc
Senior VP for Health Sciences, Tulane School of Medicine, New Orleans, LA
Abstract Submission Form
Ninth Scientific Sessions Consortium for Southeastern Hypertension Control
Savannah, Georgia  October 17 – 19, 2002

Instructions:
Type abstract within box at right. Mail original and two copies to address listed below. You may email abstracts to: bstrawn@wfubmc.edu

Deadline for Submission:
September 1, 2002

Please Mail to:
William Strawn, DVM, PhD
Hypertension-5 JCSB
Medical Center Blvd.
WFU School of Medicine
Winston-Salem, NC
27157-1032

Please direct questions to:
William Strawn, DVM, PhD
bstrawn@wfubmc.edu
336-716-5819

Travel Fellowships:
For investigators in training: please submit curriculum vitae and letter from mentor along with abstracts

Special Notice
The Scientific Poster Session will include the opportunity for investigators to be eligible to win awards in the categories of: Clinical Science, Basic Science, or Public Health.

Abstracts to be published in the American Journal of the Medical Sciences

Name: __________________________________________________________

Address: __________________________________________________________________________

City: __________________ State: _____ Zip Code: ________________

Country: __________________ Phone (_______) ______________________

Fax: ____________________ email: ________________________________
Registration Form
Visit us online: www.cosehc.org.

Registration Fee
☐ Postmarked before October 1, 2002: $375.00 for MD, PhD, DO; $275.00 for Nurses, Public Health Personnel, Residents, Spouses, Guests, Exhibitors and all others.

☐ Postmarked after October 1, 2002: $425.00 for MD, PhD, DO; $325.00 for Nurses, Public Health Personnel, Residents, Spouses, Guests, Exhibitors and all others.

Checks should be payable to: MUSC - CME (see Register by mail, etc.) Visa, Mastercard or checks. For personal assistance with registration, call MUSC at 843-876-1925

Amount enclosed: ____________________________ Credit Card Number: ____________________________

Signature: ____________________________ Expiration Date: ____________________________

Refund Policy: A processing fee of $50.00 will be charged for cancellations received at any time. Cancellations (in writing) must be received no less than ten days before the starting date of the conference in order to obtain a refund. However, we will be pleased to transfer registration to another individual in your organization at any time. If you plan to send someone in your place, please notify us as soon as possible so that materials can be prepared.

Special Needs: Call 800-267-3421

Name ____________________________ Social Security No. ____________________________

Address ____________________________ City ____________________________ State ______ Zip ______

Phone ____________________________ Fax ____________________________ Email ____________________________

Degree

Check: ☐ MD ☐ DO ☐ PhD. ☐ Nurse ☐ Public Health ☐ Resident ☐ Spouse ☐ Guest ☐ Exhibitor ☐ Other Specialty

Mail To:

MUSC - CME
Office of Continuing Medical Education
100 Doughty Street, Suite 204, P.O. Box 250754, Charleston, SC 29425
Phone: 843-876-1925

Fax registration form to: 843-876-1931
All registrations received by phone or fax must be accompanied by credit card information

Airline Travel

Delta Airlines is COSEHC’s Official Carrier. Take advantage of special lower cost negotiated air fares and car rentals by calling COSEHC’s official travel service: Danville Travel 1-800-443-4280 (Ask for Carley)

Still Have Questions?????

Registration: Call 843-876-1925

COSEHC program, speakers and COSEHC miscellaneous: Call COSEHC at 800-267-3421, Fax: 336-713-4739.

CME Credit: Call MUSC at 843-876-1925

Exhibit preparations and set ups:
Call Blue Chip Expo at 843-681-4545.

Want to Exhibit: Call COSEHC at 800-267-3421, Fax: 336-713-4739.
What Is COSEHC?

Preface
Cardiovascular disease remains the leading cause of death in the United States and other industrialized societies. Regionally, the southeastern United States has higher numbers of deaths attributable to myocardial infarction, stroke, and renal failure.

COSEHC
COSEHC is The Consortium for Southeastern Hypertension Control (originally founded under the name Consortium of Southeastern Hypertension Centers) is a nonprofit organization created in 1992 in response to a compelling need to improve the disproportionate hypertension-related morbidity and mortality throughout the region.

The consortium represents 13 states (Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia) and the District of Columbia. These states contain 26% of the US population. They have the highest prevalence of hypertension and the greatest incidence of hypertensive complications compared with other regions.

COSEHC’s Mission and Goal
The COSEHC Mission is to reduce morbidity and mortality from hypertension-related conditions (heart attack and disease, stroke, and kidney failure) in the southeastern US. The COSEHC Goal is to improve the degree of control of hypertension in the Southeastern US.

COSEHC Strategies
COSEHC defined its key strategic approach as the improvement of knowledge about hypertension and of hypertension-related problems in the Southeast. This strategic approach recognizes that much has been done already to address issues in this region and COSEHC seeks to facilitate the broader dissemination of existing best-practices. It also acknowledges that there are many gaps in the translation of data into practical knowledge at many levels in the chain of influence in healthcare. By articulating a broad strategy that seeks to improve knowledge, a number of target audiences will be distinctly identified.

COSEHC’s Target Audience
The defined target audiences are as follows: healthcare providers (physicians and nonphysician providers, such as nurses, nurse practitioners, physician assistants, pharmacists, among others); the public and patients; managed care organizations and other provider groups; and healthcare payers (employers, employer coalitions, and government).

COSEHC Membership
Membership is open to any individual concerned about hypertension in the Southeastern United States. Members have the option of subscribing to COSEHC’s official journal, the American Journal of the Medical Sciences along with their COSEHC membership. Annual meetings are held bringing together members and nonmembers.